ArticleAdvanced healthcare materials2026
Gellan Gum Fluid Gel System for Controlled-Delivery of Cytokine-Licensed MSC-EVs to Enhance Corneal Repair in Limbal Stem Cell Deficiency.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Corneal diseases such as limbal stem cell deficiency (LSCD) are major causes of blindness, and effective options for severe injury remain limited. Mesenchymal stromal cell extracellular vesicles (MSC-EVs) have immunomodulatory and regenerative activity, which can be enhanced by cytokine licensing of MSCs with TGF-β1 and IFN-γ. A key barrier is achieving sustained, localized ocular delivery. Here, we combine licensed MSC-EVs with a gellan gum fluid gel (FG), a biocompatible, shear-thinning viscoelastic system designed to improve residence time versus conventional eyedrops. Licensed MSC-EVs were isolated by size-exclusion chromatography and characterized by morphology, size, and marker expression. FG was produced by shear gelation and assessed for transparency, rheology, EV release, and cytocompatibility. EVs were spherical (102 nm) and expressed CD9, CD63, CD81, and TSG101. FG behaved as solid at rest and flowed under shear. The lead formulation released 18% of loaded EVs over 6 h, significantly outperforming comparator gels (p < 0.0001), and was non-toxic to human corneal epithelial cells and keratocytes. Released EVs accelerated closure in an in vitro corneal wound model and reduced epithelial defect and inflammation in a traumatic LSCD model in vivo. Gellan gum FG therefore enables controlled MSC-EV delivery and shows promise for treating severe corneal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.